Cindy Stahn

Summary

Affiliation: German Rheumatism Research Centre
Country: Germany

Publications

  1. doi request reprint Genomic and nongenomic effects of glucocorticoids
    Cindy Stahn
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany
    Nat Clin Pract Rheumatol 4:525-33. 2008
  2. ncbi request reprint Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
    Cindy Stahn
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Schumannstrasse 20 21, 10117 Berlin, Germany
    Mol Cell Endocrinol 275:71-8. 2007
  3. doi request reprint Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia
    Timo Gaber
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, 10117 Berlin, Germany
    J Immunol 186:764-74. 2011
  4. doi request reprint Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells
    Cornelia M Spies
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Campus Mitte, Chariteplatz 1, Berlin, Germany
    Immunol Lett 131:24-32. 2010
  5. doi request reprint Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands
    Mark Lowenberg
    Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Steroids 73:1025-9. 2008

Detail Information

Publications5

  1. doi request reprint Genomic and nongenomic effects of glucocorticoids
    Cindy Stahn
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany
    Nat Clin Pract Rheumatol 4:525-33. 2008
    ..Increased understanding of these mechanisms of glucocorticoid action could enable the development of novel drugs with which to treat patients with inflammatory and autoimmune disease...
  2. ncbi request reprint Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists
    Cindy Stahn
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Schumannstrasse 20 21, 10117 Berlin, Germany
    Mol Cell Endocrinol 275:71-8. 2007
    ..Here, we review the above-mentioned mechanisms of glucocorticoid action and give particular attention to the development of optimized glucocorticoids and SEGRAs...
  3. doi request reprint Macrophage migration inhibitory factor counterregulates dexamethasone-mediated suppression of hypoxia-inducible factor-1 alpha function and differentially influences human CD4+ T cell proliferation under hypoxia
    Timo Gaber
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, 10117 Berlin, Germany
    J Immunol 186:764-74. 2011
    ..Therefore, we suggest that HIF and/or MIF could be useful targets to optimize GC therapy when treating inflammation...
  4. doi request reprint Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells
    Cornelia M Spies
    Department of Rheumatology and Clinical Immunology, Charite University Hospital, Campus Mitte, Chariteplatz 1, Berlin, Germany
    Immunol Lett 131:24-32. 2010
    ..It is implied that these effects contribute to the well-known beneficial anti-inflammatory and immunomodulatory effects of glucocorticoid therapy...
  5. doi request reprint Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands
    Mark Lowenberg
    Department of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9, NL 1105 AZ Amsterdam, The Netherlands
    Steroids 73:1025-9. 2008
    ..As a consequence, membrane-linked GC receptors might be a potential candidate target for GC therapy. The ultimate goal is to convert these molecular insights into new GC receptor modulators with an improved therapeutic index...